William Penn Acquisition
Total Consideration
$103.2M
Share price: $29.05
Purchase-Price Allocation
Goodwill
$6.9M
Assets Acquired
$726.5M
Liabilities Assumed
$630.2M
Pro-Forma Combined Entity
Net Income
+$56.7M
2 years of history · ending 2025-12-31 · SEC EDGAR
Per-quarter consensus estimates + actuals + beat/miss surprise. Sourced from Finnhub (Wall Street consensus aggregation).
Source caveat: Finnhub free tier returns the consensus mean only — analyst high / low / dispersion + analyst counts require a paid plan. A "$5.00 consensus" line above could mean "20 analysts at exactly $5" (high conviction) or "10 at $5.50, 10 at $4.50" (split). Treat single-line consensus accordingly.
Bridges from the federal statutory rate (21% post-TCJA) to the effective tax rate via the issuer's tax-note reconciliation lines. Sourced from EffectiveIncomeTaxRateReconciliation* flat CompanyFacts concepts. Conditional lines (R&D credits, FDII, SBC, valuation allowance, etc.) only render when the issuer discloses them. Persistent divergence between accrual tax expense and cash taxes paid is a leading signal for deferred-tax buildup.
Effective Rate Trend
| Reconciliation Line | FY2019 | FY2020 | FY2021 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Federal Statutory Rate | 21.00% | 21.00% | 21.00% | 21.00% | 21.00% | 21.00% |
| State & Local Income Taxes | — | — | — | 0.40% | 1.90% | 1.10% |
| Foreign Rate Differential | — | — | — | — | — | — |
| Other Adjustments | — | — | — | -0.80% | 0.60% | 0.50% |
| SBC (Nondeductible) | — | — | — | 0.00% | 0.00% | 0.30% |
| Effective Tax Rate | — | — | — | 16.30% | 17.60% | 22.30% |
Cash vs Accrual
| Item | FY2019 | FY2020 | FY2021 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Income Tax Expense (Accrual) | $3.7M | $5.1M | $6.7M | $7.3M | $10.6M | $16.1M |
| Income Taxes Paid (Cash) | — | — | — | — | — | $5.8M |
Per-deal acquisition disclosures sourced from us-gaap:BusinessAcquisitionAxis dimensional XBRL. Each card surfaces the deal's purchase-price allocation (goodwill vs intangibles vs liabilities), contingent consideration (unpaid earn-outs), and pro-forma combined-entity numbers. Probability-of-Success (PoS) factor on biotech targets is the ASC 805 contingent-consideration valuation — higher = closer to commercialization, higher implied target value.
Total Consideration
$103.2M
Share price: $29.05
Purchase-Price Allocation
Goodwill
$6.9M
Assets Acquired
$726.5M
Liabilities Assumed
$630.2M
Pro-Forma Combined Entity
Net Income
+$56.7M
Total Consideration
$5.5M
Total Consideration
$4.0M
Purchase-Price Allocation
Goodwill
$1.6M
Total Consideration
$2.0M
Purchase-Price Allocation
Goodwill
$1.1M
Contingent Earn-Out
$800.0K
Share price: $18.50
Phase 1: currency selection stored in the URL. Conversion ships in Phase 2 (see ADR-0003).